Immune profiling and biomarker platforms to support pre-clinical research

WuXi Biology provides discovery and clinical biomarker services for immuno-oncology research. Our technology platform includes a CAP-certified pathology lab, a flow cytometry and molecular biology lab, and GCP compliance. Our team is composed of highly-trained immunologists, board-certified pathologists, and biomarker experts.

Flow Cytometry

  • >20 channel flow cytometry analysis
  • Cover >60 cell marker/biomarker
  • Baseline TIL (tumor-infiltrating leukocytes) data from >30 models
  • Service covered TIL analysis
  • Checkpoint/co-stimulatory marker analysis
  • in vitro/in vivo phospho-flow
  • Function analysis of immune cells
  • High dimensional data mining
  • View our comprehensive CD34+ Hematopoietic Stem Cell Differentiation Platform

Pathology/Multiplex IF

  • FFPE preparation/IHC/IF to support pre-clinical pathology diagnosis for drug safety evaluation, efficacy evaluation, etc.
  • Multiplex IF focusing on immune microenvironment analysis, including
    • Immune cell infiltration analysis
    • Spatial-proximity analysis
    • Secretory protein source determination
    • Complex tissue structure determination
    • Evaluation of gene expression regulation
  • Provide biomarker testing services for clinical studies, including:
    • H&E and histology analysis
    • FFPE sample process and slide cutting
    • IHC/ICC,IF, EHC, TCT, FISH, DISH, RNAscope, and multiplex-IF

Case study: Optimization of human tumor dissociation process to eliminate hTIM-3 and hLAG-3 degradations

Biomarkers, qPCR, FFPE, multiplex, NGS, IHC, FISH, single-cell RNAseq, NanoString gene expression

NanoString-based gene expression profiling

  • Gene expression profiling with up to 800 genes in one panel
  • Enabling GEP in difficult samples like FFPE
  • Panel covering hot genes/pathways/function in immunology/oncology

Single-cell RNA sequencing platform and bioinformatics services

  • One-stop service covering sample processing, library preparation, sequencing, and bioinformatics analysis.
  • Enabling cell type identification and phenotyping, differential gene expression analysis, functional enrichment, and cell-cell interaction.

Molecular platform

  • Quantitative polymerase chain reaction (qPCR) to support efficacy and safety evaluation (e.g. target gene copy number variation in CAR-T cells, and replication competent lentivirus (RCL) level in CAR-T cells).
  • cMET exon14 skipping and EGFR mutation testing.

Related Resources View All

mRNA-Encoded Modulators Suppress Tumor Growth

Resource Type: Latest Science Poster

Cancer Pharmacology Services

Resource Type: Brochure

NK Cell Humanized Tumor Models

Resource Type: Latest Science Presentation